Veraxa Biotech AG is a biotechnology company focused on the development of innovative therapeutic solutions for various medical conditions. The firm's cutting-edge research is concentrated on utilizing advanced biotechnological platforms to potentially transform patient care through novel drug development. With a robust pipeline and commitment to scientific excellence, Veraxa is positioned to address unmet medical needs across multiple therapeutic areas. The company’s strategic vision is to leverage its proprietary technologies to deliver breakthrough treatments, ultimately enhancing the quality of life for patients worldwide. As it progresses through clinical trials, Veraxa aims to attract strategic partnerships and investors to support its growth trajectory in the competitive biotech landscape.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | 89.31 |
| Price-to-Sales (TTM) | 9623.30 |
| EV/Revenue | 9645.79 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $141.41M |
| Float | 0 |
| % Insiders | 71.15% |
| % Institutions | 11.81% |
ZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update. “In the first six months of 2026, we have made substantial progress in honing our pipeline and partnering strategy.
ZURICH, SWITZERLAND – July 02, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC® T-cell engager (BiTAC-TCE) program. VERAXA has engaged ATUM, a global leader in bioengineering and cell line development, to apply the proprietary Leap-In Transposase® technology to support stable clonal cell line generation.
VERAXA Biotech has moved into additional laboratory space at its R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement.
ZURICH, SWITZERLAND – June 18, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform and its potential to enable more precise and targeted cancer therapies. VERAXA will attend the BIO International Convention in San Diego, Calif.
